The incorporation of the S6P mutation in the Delta and BA.1 variant spike proteins significantly enhances the efficacy of mRNA-based COVID-19 vaccines, as demonstrated by the robust immune responses and protection observed in preclinical models. Here, CHMP5 is linked to COVID-19.